Advertisement
Advertisement
ALKS
Alkermes Inc. plc
49.48
USDSponsored
-0.37
-0.74%
Aug 18, 15:59 UTC -4
Closed
After-Market
49.48
+0.01
+0.01%
ALKS Earnings Reports
Positive Surprise Ratio
ALKS beat 34 of 43 last estimates.
79%
Next Report
Date of Next Report
Oct 26, 2026
Estimate for Q3 26 (Revenue/ EPS)
$473.16M
/-$0.08
Implied change from Q2 26 (Revenue/ EPS)
-4.61%
/--
Implied change from Q3 25 (Revenue/ EPS)
+20.03%
/-116.33%
Alkermes Inc. plc earnings per share and revenue
On Jul 28, 2026, ALKS reported earnings of 0.00 USD per share (EPS) for Q2 26, beating the estimate of -0.02 USD, resulting in a 100.00% surprise. Revenue reached 496.01 million, compared to an expected 466.97 million, with a 6.22% difference. The market reacted with a -4.23% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 9 analysts forecast an EPS of -0.08 USD, with revenue projected to reach 473.16 million USD, implying an -- of --% EPS, and decrease of -4.61% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Celcuity Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.18
Actual
-$1.44
Surprise
-21.23%
Cabaletta Bio, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.34
Surprise
+10.69%
Prenetics Global Limited Class A Ordinary Share
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.71
Actual
-$0.53
Surprise
+26.30%
TuHURA Biosciences, Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+5.34%
ProMIS Neurosciences Inc. Common Shares (ON)
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.39
Actual
-$1.28
Surprise
+8.07%
Outlook Therapeutics, Inc. Common Stock
Report Date
Aug 14, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.09
Surprise
+5.46%
Elutia Inc. Class A Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-11.11%
Lantern Pharma Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.28
Surprise
+27.76%
Kyntra Bio, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$3.24
Actual
-$4.68
Surprise
-44.15%
PDS Biotechnology Corporation Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.18
Surprise
-35.75%
FAQ
What were Alkermes Inc. plc's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Alkermes Inc. plc reported EPS of $0.00, beating estimates by 100%, and revenue of $496.01M, 6.22% above expectations.
How did the market react to Alkermes Inc. plc's Q2 2026 earnings?
The stock price moved down -4.23%, changed from $52.73 before the earnings release to $50.50 the day after.
When is Alkermes Inc. plc expected to report next?
The next earning report is scheduled for Oct 26, 2026.
What are the forecasts for Alkermes Inc. plc's next earnings report?
Based on 9
analysts, Alkermes Inc. plc is expected to report EPS of -$0.08 and revenue of $473.16M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement